GABBR1
Gamma-aminobutyric acid type B receptor subunit 1
As of the edition of 20 October 2026, GABBR1 (gamma-aminobutyric acid type B receptor subunit 1, UniProt Q9UBS5) has 6 drugs tested at it and 21 companies on the list, 4 on route A and 2 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- Q9UBS5
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- In more than one place
- Solved structures
- 24
- Disease areas
- Nervous system; Mental health; Chemically induced; Bones, joints and muscles; Digestive system; Immune system; Inherited and neonatal; Injuries
- Registered trials of its drugs
- 152
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 2 |
| Went quiet | 3 |
| Stopped | 1 |
| Total | 6 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Baclofen | Marketed | Phase 4 | none listed |
| Oxybate | Marketed | Phase 4 | Ends 2028 |
| Arbaclofen | Stopped | Phase 3 | none listed |
| Lesogaberan | Went quiet | Phase 2 | none listed |
| Arbaclofen placarbil | Went quiet | Phase 2 | none listed |
| SGS-742 | Went quiet | Phase 2 | none listed |
6 of 6 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 4 |
| Route B | 2 |
| Undetermined | 15 |
| Total on the list | 21 |
| Company | Route |
|---|---|
| AstraZeneca | Route A |
| Jazz Pharmaceuticals | Route B |
| UCB | Route B |
The other 18 companies at GABBR1
In the product21 companies in all; 18 are not named here, and no score is.
See the 21 companies at GABBR1, ranked, with the facts behind eachRequest access. Nothing is shown until you do.